INGELHEIM, Germany. - Monday, August 25th 2014

    HOT LINE: New results from RE-LY® compare the effect of warfarin and Pradaxa® on kidney function in patients requiring anticoagulation
    HOT LINE: GLORIA™-AF Registry Program benchmarks patient characteristics and antithrombotic use for stroke prevention in AF worldwide

For Non-US/Non-UK/Non-Canadian Media

New Pradaxa® (dabigatran etexilate) data for the treatment of a broad range of thromboembolic diseases will be presented at the ESC Congress 2014, 30th August – 3rd September, 2014, Barcelona, Spain, organised by the European Society of Cardiology. Study results, including data being presented in two Hot Line sessions, will provide further clinical insights for Pradaxa® and help inform future anticoagulation treatment decisions.

    On August 31st, the Registry Hot Line session will reveal data from the first 10,000 patients included in the GLORIA™-AF Registry Program, which will provide insights into patterns of antithrombotic treatment use for stroke prevention in atrial fibrillation (AF).
    On September 2nd, a Clinical Trial Update Hot Line session will announce new data from a RE-LY® sub-analysis comparing the effects of warfarin and Pradaxa® on kidney function in AF patients requiring anticoagulation.
    Further new data sets from company-sponsored studies involving Pradaxa® in AF, deep vein thrombosis and pulmonary embolism will also feature as poster and oral presentations during the ESC Congress 2014.

Abstracts are available from the ESC website at: http://spo.escardio.org/default.aspx?eevtid=69

In Barcelona, five years ago, the landmark RE-LY® study results were presented at the ESC Congress 2009. Since then, the RE-LY® findings have been reconfirmed in numerous sub-analyses, supported by Regulatory Authorities worldwide and were most recently replicated outside of a clinical study setting by an independent FDA assessment involving more than 134,000 Medicare patients.1-4

Boehringer Ingelheim will be hosting a media briefing during the ESC congress to present the new data, discuss how Pradaxa® is impacting patients in everyday clinical practice and give an update on the ongoing R&D programme including the progress of the investigational antidote idarucizumab. Medical media who are interested in attending the Boehringer Ingelheim briefing ‘Setting the Record Straight - Pradaxa® Protection Today and Tomorrow’ on Monday 1st September, 14.00-15.00 in the Industry Press Conference Room, should contact pradaxa@ogilvy.com

Contacts

Boehringer Ingelheim

Corporate Communications

Media + PR

Friederike Middeke

Phone: +49 6132 – 77 141 575

Fax: +49 6132 – 77 6601

Email: press@boehringer-ingelheim.com

Permalink: http://www.me-newswire.net/news/11903/en